Practical and concise synthesis of nucleoside analogs
- PMID: 35788720
- DOI: 10.1038/s41596-022-00705-7
Practical and concise synthesis of nucleoside analogs
Abstract
Nucleoside analogs are valuable commodities in the development of antisense oligonucleotides or as stand-alone antiviral and anticancer therapies. Syntheses of nucleoside analogs are typically challenged by a reliance on chiral pool starting materials and inefficient synthetic routes that are not readily amenable to diversification. The novel methodology described in this protocol addresses several longstanding challenges in nucleoside analog synthesis by enabling flexible and selective access to nucleoside analogs possessing variable nucleobase substitution, D- or L-configuration, selective protection of C3'/C5' alcohols and C2' or C4' derivatizations. This protocol provides direct access to C3'/C5' protected nucleoside analogs in three steps from simple, achiral starting materials and is described on both research (2.8 g) and process (30 g) scales for the synthesis of C3'/C5'-acetonide protected uridine. Using this protocol, proline catalyzes the fluorination of simple heteroaryl-substituted aldehyde starting materials, which are then directly engaged in a one-pot enantioselective aldol reaction with a dioxanone. Reduction, followed by intramolecular annulative fluoride displacement, forges the nucleoside analog. The three-step parent protocol can be completed in ~5 d by using simple mix-and-stir reaction procedures and standard column chromatographic purification techniques.
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.
References
-
- Shelton, J. et al. Metabolism, biochemical actions, and chemical synthesis of anticancer nucleosides, nucleotides, and base analogs. Chem. Rev. 116, 14379–14455 (2016). - DOI
-
- First Oral Antiviral for COVID-19, Lageviro (molnupiravir), approved by MHRA. Medicines and Healthcare products Regulatory Agency (MHRA) (Press release). 4 November 2021. Retrieved 23 November 2021. https://www.gov.uk/government/news/first-oral-antiviral-for-covid-19-lag...
-
- Merck and Ridgeback’s Molnupiravir, an Oral COVID-19 Antiviral Medicine, Receives First Authorization in the World. Merck & Co. (Press release). 4 November 2021. Retrieved 23 November 2021. https://www.merck.com/news/merck-and-ridgebacks-molnupiravir-an-oral-cov...
-
- Kim, J. et al. Patient-customized oligonucleotide therapy for a rare genetic disease. N. Engl. J. Med. 381, 1644–1652 (2019). - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous